C. difficile

Finch was still able to continue dosing patients in its past-ongoing PRISM-EXT phase 2 open-label trial of CP101 in recurrent CDI, because the CP101 lots used for PRISM-EXT were manufactured from material donated prior to December 1, 2019.

Novel C. difficile infection (CDI) vaccine shows promise lowering the severity of CDI and in preventing medically attended CDI.

Links of chain mail are arranged in the bacteria to form a pattern that prevents molecules from entering the cell.

Hospital-onset clostridium difficile infections frequently occur because of both patient and environmental risk factors.

The drug pipeline is insufficient to meet the threat of antimicrobial resistance, and policy reforms are critically needed, according to the Biotechnology Innovation Organization.

Fecal microbiota transplantation produces cure rates of 82%-88% in patients with recurrent clostridium difficile infections.

Lower use of antimicrobials for clostridium difficile infection associated with a shorter length of stay in hospitals.

A machine-learning method called XGBoost provided the highest overall accuracy, despite being the least complex model.

Finding alternative means to promote interleukin 25 could enhance the benefits of fecal transplants in patients with recurrent C. difficile infections.

The Microbiome Health Index for post-Antibiotic dysbiosis was developed to improve the understanding of and manage the risks associated with antibiotic administration.

Pharmacists play an important role in educating patients and other health care practitioners on the signs and symptoms of C. difficile infection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed the current burden of C. diff infection and recurrent C. diff infection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, addressed the risk factors for C. diff infection and recurrent C. diff infection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, addressed the relationship between gut microbiome and C. diff infection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discusses the current treatment strategies for C. diff infection and recurrent C. diff infection, as well as the efficacy and safety of these treatments.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, explains what the gut-brain axis is and how microbiome impacts this connection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed the role of the microbiome in overall patient health and recurrent Clostridioides difficile infection.

The panelists reviewed current treatments for Clostridioides difficile infection and how they can be applied to special patient populations, as well as what treatments can be expected in the future.

Using a non-aqueous vehicle and sweeteners to improve palatability, pharmacists and technicians can ensure that young patients remain medication adherent.

An overview of the risk factors that contribute to the development of Clostridioides difficile infection in various health care settings.

Debra Goff, PharmD, FIDSA, FCCP, infectious diseases specialist at the Ohio State University Wexner Medical Center, discusses Clostridioides difficile awareness and potential future treatments.

Comprehensive discussion on the identification of Clostridioides difficile infection, the spectrum of disease, and overall epidemiology.

The panel reflects on how disruption of the gut microbiome leads to the proliferation of Clostridioides difficile.

Shared insight on how disruption of the gut microbiome may occur based on antibiotic exposure, environmental factors, and diet.

Opening their discussion on Clostridioides difficile, experts provide an overview on the gut microbiome and colonization resistance.

PRISM-EXT shows data consistent with those of PRISM3, which provided significant improvement compared with the placebo through 8 weeks and 24 weeks post-treatment.

SER-109, an investigational, oral, biologically-sourced microbiome therapeutic designed to reduce recurrence of C. difficile infection (CDI), demonstrated a 31.1% absolute reduction in the rate of CDI recurrence over 12 weeks compared to placebo

The concentration of C. diff toxins in the stool was linked to how sick patients were at the time of diagnosis and was associated with adverse outcomes, including the risk of infection returning after treatment.

A diagnosis of Clostridioides difficile infection does not instantly require treatment, but new guidelines include recommendations for treatment when warranted.